Nevrox
Therapeutic Small Molecule Inhibitor for Treating Neurodegenerative Disorders
Health Tech & Life Sciences
Non Active, Sep 2022 ceased to operate
Company Overview
Snapshot
Founded in July 2019 by Niva Segev-Amzaleg and Brent Stockwell, Nevrox operates with 1–10 employees. The company secured its seed funding round in November 2019, with participation from RMGP Biopharma Investment Fund and FutuRx.
Business overview
Nevrox is a drug discovery company focused on developing a neuroprotective small molecule modulator of protein disulfide isomerase (PDI). This technology aims to treat neurodegenerative disorders such as Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical industry with its biotechnology and drug discovery efforts.
Company Intelligence Q&A
- What is Nevrox's primary focus?
- Nevrox is a drug discovery company developing a neuroprotective small molecule modulator of protein disulfide isomerase (PDI) for the treatment of Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
- When was Nevrox founded?
- Nevrox was founded in July 2019.
- Who are the founders of Nevrox?
- Nevrox was founded by Niva Segev-Amzaleg and Brent Stockwell.
- What is the current status of Nevrox?
- Nevrox is currently non-active and ceased to operate in September 2022.
- Which investors participated in Nevrox's seed funding round?
- In November 2019, Nevrox secured seed funding from RMGP Biopharma Investment Fund and FutuRx.